Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ONC, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Zanubrutinib FDA approved Nov 2019 · Brukinsa (discontinued) |
Mantle Cell Lymphoma | Phase 3 · NCT06742996 | Recruiting |
| Sonrotoclax (BGB-11417) FDA approved May 2026 · Beqalzi |
Mantle Cell Lymphoma | Phase 3 · NCT06742996 | Recruiting |
| Anti-GPC3/Anti-4-1BB Bispecific Antibody… | Hepatocellular Carcinoma | Phase 3 · NCT07836530 | Not yet recruiting |
| CDK4 Inhibitor BGB-43395 | HR+/HER2- Breast Cancer | Phase 3 · NCT07492641 | Recruiting |
| Idelalisib | CLL | Phase 3 · NCT06846671 | Recruiting |
| Fluorouracil | Metastatic Gastric Adenocarcinoma | Phase 3 · NCT07043400 | Recruiting |
| Bendamustine | CLL | Phase 3 · NCT06846671 | Recruiting |
| Tacabrutideg | Chronic Lymphocytic Leukemia | Phase 3 · NCT06973187 | Recruiting |
| Programmed Cell Death Protein 1 | Borderline Resectable Carcinoma | Phase 2 · NCT07339488 | Recruiting |
| Cytotoxic Chemotherapeutic Agent | Borderline Resectable Carcinoma | Phase 2 · NCT07339488 | Recruiting |
| Chimeric Antigen Receptor T-cells | Mantle Cell Lymphoma | Phase 2 · NCT07341191 | Recruiting |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor… | Solid Tumors | Phase 1 · NCT07181681 | Recruiting |
| BG-T0050 | Diffuse Large B-Cell Lymphoma | Phase 1 · NCT07881211 | Not yet recruiting |
| Rosuvastatin | Healthy Adult Participants | Phase 1 · NCT07820891 | Recruiting |
| Anti-B7-H4 Antibody Drug Conjugate BG-C9074 | Advanced Solid Tumor | Phase 1 · NCT06233942 | Recruiting |
| Anti-CEACAM5 Antibody-drug Conjugate BG-C477 | Advanced Solid Tumors | Phase 1 · NCT06596473 | Recruiting |
Also used in these trials (approved or third-party drugs, not ONC's own candidates): Rituximab, Cisplatin, Lenvatinib, Letrozole, Leucovorin, Lenalidomide, Obinutuzumab, Capecitabine, Oxaliplatin, Palbociclib, Tislelizumab, Pirtobrutinib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ONC holds $5.1B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ONC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Julian C. Baker | Institution (13G, 5%+) | 115,912,814 | 7.81% | 2026-09-14 |
| Lai Wang President, Global Head of R&D · +229,775 options |
Insider | 601,965 | 0.04% | 2026-06-23 |
| BAKER BROS. ADVISORS LP Director |
Insider | 323,097 | 0.02% | 2026-09-14 |
| John Oyler Chief Executive Officer, Director · +344,679 options |
Insider | 102,188 | 0.01% | 2026-08-10 |
| Anthony C Hooper Director |
Insider | 83,720 | 0.01% | 2026-06-11 |
| Margaret Dugan Director |
Insider | 73,164 | 0.00% | 2026-06-11 |
| Alessandro Riva Director |
Insider | 73,164 | 0.00% | 2026-06-11 |
| Olivier Brandicourt Director |
Insider | 46,306 | 0.00% | 2026-06-11 |
| Elizabeth Fisher Mooney Director |
Insider | 18,980 | 0.00% | 2026-06-11 |
| Xiaobin Wu President and COO · +229,775 options |
Insider | 4,000 | 0.00% | 2026-08-25 |
| Charles Lazelle Sawyers Director |
Insider | 1,946 | 0.00% | 2026-06-11 |
| Xiaodong Wang Director · +193,492 options |
Insider | 50 | 0.00% | 2026-10-27 |
Share count 1,484,939,031 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ONC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →